CASI is a biopharmaceutical company focused on the acquisition, development, and commercialization of quality pharmaceuticals and innovative therapeutics addressing CANCER and other unmet medical needs for the global market, with a focus on greater China and the U.S. We are a NASDAQ-listed company, headquartered in Rockville, Maryland with a wholly owned subsidiary and R&D operations in Beijing, China.
Our mission is to become an integrated biopharmaceutical company with significant market share in China, while establishing partnerships for global development and commercialization. Part of our strategy is to leverage our expertise and resources in China and the U.S. to bring high-quality pharmaceuticals and innovative oncology products to patients and to develop them faster and more cost-effectively using our dual China-U.S. development approach.
We have a strong and growing product pipeline of commercially available and clinical stage drug candidates, and will continue to (i) acquire additional approved and clinical stage drug candidates through in-license and acquisitions, and (ii) explore drug candidates in preclinical development.
CASI’s product portfolio includes (1) EVOMELA® (melphalan) for injection, MARQIBO®, (vinCRIStine sulfate LIPOSOME injection), ZEVALIN®, (ibritumomab tiuxetan), all U.S. Food and Drug Administration (FDA) approved drugs in-licensed from Spectrum Pharmaceuticals, Inc. for China regional rights that are currently in various stages in the regulatory and clinical process for market approval in China, (2) ENMD-2076 (Phase 2) (3) entecavir for hepatitis B and the other U.S. ANDA products, (4) CASI-001 and CASI-002, proprietary immuno-oncology preclinical candidates.